Use of biogenic estrogen sulfamates for hormone replacement therapy

US7053077B1 · kind B1 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Walter Elger · Berlin, DE
• Pekka Lähteenmäki · Turku, FI
• Matti Lehtinen · Kaarina, FI
• Gudrun Reddersen · Jena, DE
• Holger Zimmermann · Falkensee, DE
• Michael Oettel · Jena, DE
• Sigfrid Schwarz · Jena, DE

Key dates

• Filing date: May 13, 1999
• Grant date: May 30, 2006
• Expiry date: May 13, 2019

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P15/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the use of biogenic estrogen sulfamates for the oral discontinuous application for hormone replacement therapy (HRT). The discontinuous administration takes place in intervals ranging from 2 to 40 days. The invention also provides the additional application of gestagens, preferably continuously in the form of an implant or in the form of an intrauterine releasing system (IUD). Estrone sulfamate, estradiol sulfamate or an N-acyl sulfamate of estrone, estradiol or estriol having up to 7 C-atoms in the acyl chain, or a combination comprised of two or more of said active ingredients are used as biogenic estrogen sulfamates.